Two-Target Immunotherapy Shows Early Promise in Eye Cancer

Adults with metastatic uveal melanoma may see a new combination trial open, based on early results from small patient groups.

Updated on Nov. 6, 2026 in Cancer

Two-Target Immunotherapy Shows Early Promise in Eye Cancer

Immunocore presented early results on Friday at the Society for Immunotherapy of Cancer annual meeting, showing a combination of its marketed drug Kimmtrak with the investigational T-cell engager brenetafusp produced a 29% overall response rate in first-line patients with unresectable or metastatic uveal melanoma. The company plans to launch the randomised Phase II/III DUET-UVEAL study to evaluate the combination in this population.

Why it matters

Uveal melanoma is a rare eye cancer that has spread or cannot be surgically removed, and treatment options for it are limited. Because the combination targets two different antigens, gp100 and PRAME, it represents an effort to extend benefit beyond what a single target currently offers, which is why the company is moving toward a larger randomised trial.

These are early Phase I/II results from small patient groups: 17 first-line combination patients and 16 brenetafusp monotherapy patients. The combination's 29% overall response rate and 8.1-month median progression-free survival have not yet been compared against Kimmtrak alone in a randomised study, which is what DUET-UVEAL is designed to do.

The players

Immunocore

A biotechnology company developing ImmTAC T-cell engager therapies for cancer, including the marketed melanoma drug Kimmtrak.

Society for Immunotherapy of Cancer (SITC)

A professional society that hosts an annual meeting where researchers present immunotherapy advances for cancer.

The details

Kimmtrak (tebentafusp) targets the antigen gp100 and has been approved since 2022 for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Brenetafusp targets PRAME, an antigen linked to poor prognosis in this cancer, and both drugs belong to a class called ImmTAC molecules that direct the immune system's T cells toward tumor cells. Combining the two aims to attack the tumor through two separate antigen targets rather than one. Among first-line combination patients, the disease control rate was 71%, and 77% experienced cytokine release syndrome, an immune-related side effect that clinicians monitor closely.

Timeline

  1. 2022: Kimmtrak was approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  2. April: Positive Phase II/III results for darovasertib in the OptimUM-02 study were reported.

  3. June: Data cut-off for the combination study, with 10 patients still on study.

  4. Friday: Early results were presented at the Society for Immunotherapy of Cancer annual meeting.

Health Landscape

Kimmtrak was approved in 2022 as a T-cell engager for a rare, hard-to-treat eye cancer, establishing this drug class in oncology. The combination with brenetafusp follows that precedent by adding a second antigen target to the same platform.

Adults with metastatic or unresectable uveal melanoma may want to ask their oncologist about whether clinical trials such as DUET-UVEAL are an option for them. Because these results are early and drawn from small groups, the combination should be seen as promising rather than established, and treatment decisions belong in a conversation with a physician.

The takeaway

Targeting two cancer antigens at once is a promising strategy that researchers are now testing in a larger randomised trial. Anyone with uveal melanoma who is weighing options should raise clinical trial eligibility with their oncologist.

What happens next

Immunocore plans to launch the randomised Phase II/III DUET-UVEAL study comparing the combination against current treatment, though no start date was given in the source.

Further reading

For background on how these therapies fit into cancer care, explore our Cancer coverage.

Source note: This article includes information reported by Firstwordpharma.